On February 16, 2024, the Food and Drug Administration (FDA) announced the approval of osimertinib, marketed under the brand name Tagrisso by AstraZeneca Pharmaceuticals LP, in combination with platinum-based chemotherapy. This approval offers a new treatment avenue for adult patients battling locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by specific genetic mutations: … Continue reading New FDA Approval: Osimertinib (TAGRISSO®) Combined with Chemotherapy for Treating EGFR-Mutated NSCLC